[go: up one dir, main page]

WO2023019174A3 - Antibodies to sars-cov-2 - Google Patents

Antibodies to sars-cov-2 Download PDF

Info

Publication number
WO2023019174A3
WO2023019174A3 PCT/US2022/074769 US2022074769W WO2023019174A3 WO 2023019174 A3 WO2023019174 A3 WO 2023019174A3 US 2022074769 W US2022074769 W US 2022074769W WO 2023019174 A3 WO2023019174 A3 WO 2023019174A3
Authority
WO
WIPO (PCT)
Prior art keywords
coronavirus
sars
cov
antibodies
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2022/074769
Other languages
French (fr)
Other versions
WO2023019174A4 (en
WO2023019174A2 (en
Inventor
John Paul Alderete
Robin J. HELLEN
Kathleen Anne KENNEDY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apollos Diagnostics LLC
Original Assignee
Apollos Diagnostics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apollos Diagnostics LLC filed Critical Apollos Diagnostics LLC
Publication of WO2023019174A2 publication Critical patent/WO2023019174A2/en
Publication of WO2023019174A3 publication Critical patent/WO2023019174A3/en
Publication of WO2023019174A4 publication Critical patent/WO2023019174A4/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C07K16/104—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for the 2019-20 coronavirus pandemic, has infected humans around the world, causing the coronavirus disease 2019 (COVID-19).The disclosure provides for certain monoclonal antibodies and/or antigen-binding fragments that selectively bind to a coronavirus protein, and more specifically, selectively binds to a protein of SARS-Co V-2 and its variant strains, and methods of use of the disclosed antibodies and antigen-binding fragments.
PCT/US2022/074769 2021-08-11 2022-08-10 Antibodies to sars-cov-2 Ceased WO2023019174A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163231848P 2021-08-11 2021-08-11
US63/231,848 2021-08-11

Publications (3)

Publication Number Publication Date
WO2023019174A2 WO2023019174A2 (en) 2023-02-16
WO2023019174A3 true WO2023019174A3 (en) 2023-07-06
WO2023019174A4 WO2023019174A4 (en) 2023-08-03

Family

ID=85200968

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/074769 Ceased WO2023019174A2 (en) 2021-08-11 2022-08-10 Antibodies to sars-cov-2

Country Status (1)

Country Link
WO (1) WO2023019174A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117143227B (en) * 2023-07-07 2024-03-12 广州海关技术中心 Specific antibody for combining coronavirus SARS-CoV-2 and SARS-CoV nucleocapsid protein and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200062836A1 (en) * 2016-11-16 2020-02-27 Eli Lilly And Company THERAPY FOR METATASTIC COLORECTAL CANCER USING ANTI-VEGFR-2 and ANTI-VEGF-D ANTIBODIES
US20200181256A1 (en) * 2012-02-24 2020-06-11 Abbvie Stemcentrx Llc Anti sez6 antibodies and methods of use
CN113234145A (en) * 2020-08-12 2021-08-10 中山大学附属第五医院 Antibodies that specifically bind to novel coronaviruses

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200181256A1 (en) * 2012-02-24 2020-06-11 Abbvie Stemcentrx Llc Anti sez6 antibodies and methods of use
US20200062836A1 (en) * 2016-11-16 2020-02-27 Eli Lilly And Company THERAPY FOR METATASTIC COLORECTAL CANCER USING ANTI-VEGFR-2 and ANTI-VEGF-D ANTIBODIES
CN113234145A (en) * 2020-08-12 2021-08-10 中山大学附属第五医院 Antibodies that specifically bind to novel coronaviruses

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE NUCLEOTIDE ANONYMOUS : "Mus musculus aberrantly recombined kappa chain Vk8/J1 region gene, partial cds", XP093078346, retrieved from NCBI *
DATABASE PROTEIN ANONYMOUS : "Chain L, ZV-64 Antibody Fab Light Chain", XP093078344, retrieved from NCBI *

Also Published As

Publication number Publication date
WO2023019174A4 (en) 2023-08-03
WO2023019174A2 (en) 2023-02-16

Similar Documents

Publication Publication Date Title
PH12021550793A1 (en) Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments
BR112022018949A2 (en) HUMAN MONOCLONAL ANTIBODIES FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2)
MX2024006462A (en) Anti-tmprss2 antibodies and antigen-binding fragments.
EP4623992A3 (en) Antibodies specifically binding to human il-1r7
PE20210132A1 (en) ANTI-CD3 ANTIBODIES AND USES OF THEM
PE20200294A1 (en) ANTIBODIES THAT SPECIFICALLY BIND PD-1 AND METHODS OF USE
WO2010010467A3 (en) Neutralizing anti-influenza a virus antibodies and uses thereof
MX2019004779A (en) Pharmaceutical composition for cancer treatment and/or prevention.
CO2020013833A2 (en) Anti-programmed death antibody-ligand 1 and its use
WO2021239935A9 (en) Neutralizing antibodies against sars-related coronavirus
CA3179819A1 (en) Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
MX2021015298A (en) HUMAN ANTI-EPHA4 ANTIBODY.
CN115666649A (en) Novel pharmaceutical composition of coronavirus antibody and application thereof
MX2022009476A (en) ANTl-TMPRSS2 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS.
CR20220660A (en) METHODS FOR TREATING OR PREVENTING SARS-CoV-2 INFECTIONS AND COVID-19 WITH ANTI-SARS-CoV-2 SPIKE GLYCOPROTEIN ANTIBODIES
WO2021212049A3 (en) Anti-sars-cov-2 monoclonal antibodies
BR112021021281A2 (en) Monoclonal antibody that specifically binds to gitr
PE20141683A1 (en) SPECIFIC MONOCLONAL ANTIBODIES FOR RESPIRATORY SYNCITIAL VIRUS (RSV) M2-1 ANTIGEN
WO2022204713A3 (en) Antibodies to sars-cov-2
WO2023019174A3 (en) Antibodies to sars-cov-2
WO2021195385A8 (en) HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
PH12022551151A1 (en) Anti-varicella-zoster virus antibody
JP2013538813A5 (en)
WO2020191181A9 (en) Monoclonal antibodies for prevention and treatment of herpes simplex viral infections
WO2022020636A3 (en) Immunogens derived from sars-cov2 spike protein

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22856792

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22856792

Country of ref document: EP

Kind code of ref document: A2